InvestorLens

CBIO — CRESCENT BIOPHARMA INC.

Public company

Sign in to save2 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying CBIO?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
65
Institutional Conviction
Net distribution · 0 buying vs 0 selling last quarter
32
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

No tracked investor changed their CBIO position last quarter. Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +2 tracked investors reported holding CBIO at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About CRESCENT BIOPHARMA INC. (CBIO)

CRESCENT BIOPHARMA INC. (CBIO) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $7M. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in CBIO

100
/100
Strong Institutional Accumulation
Added / Increased1
Reduced0
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track CBIO

13
/100
Undiscovered
2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded
151015+

CBIO Ownership Composition

How CRESCENT BIOPHARMA INC. is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
2
tracked investors
Total Reported
$12.7M
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(2)
100.0%

Tracked investors currently reporting CBIO

1 tracked investor has since exited this position — listed separately below.

  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    403.9K
    Value
    $7.3M
    % Portfolio
    0.00%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    300K
    Value
    $5.4M
    % Portfolio
    0.01%

Previously held CBIO

These investors reported CBIO in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Ken GriffinCitadel Advisors25.6K$304.3KSep 30, 2025

Recent activity

Frequently asked questions

How many institutional investors hold CBIO?
2 tracked institutional investors disclosed a position in CBIO (CRESCENT BIOPHARMA INC.) in their most recent 13F filing.
Who is the largest institutional holder of CBIO?
Izzy Englander, Millennium Management, holds the largest disclosed position in CBIO, valued at $7M.
Did institutional ownership of CBIO increase or decrease?
Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 0 fully exited CBIO.
Where does this CBIO ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
CBIO (CRESCENT BIOPHARMA INC.) — Institutional Holders & — InvestorLens